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Antidepressants have good efficacy in the treatment of
mood disorders, with effect sizes that have consistently
been found to be greater than those of placebo. The
more recent antidepressants do not have better efficacy
than the compounds discovered 40 to 50 years ago, but
they do have a more favorable configuration of side
effects, leading to fewer dropouts. This favorable situation
has made it possible to prescribe the newer antidepres-
sants in less severe depression and in several anxiety dis-
orders, with considerable benefit to patients. During the
last decades, research into the pathophysiology of mood
and anxiety disorders has provided much information on
the brain circuitry, neurohormones, and neurotransmit-
ters involved in these disorders. In parallel, biological and
behavioral work on antidepressants, using animal models
and new biochemical techniques, has led to a broader
understanding of the mode of action of these drugs.
Despite this impressive list of discoveries, much research
remains to be done on the clinical, psychological, neu-
ropsychological, physiological, and neurochemical aspects,
before we can obtain a coherent description of the patho-
physiological mechanisms of depression and its treatment.
This will lead to a better ability to predict the quality of
drug response and, therefore, to the individualization of
treatment. 
his review concerns the clinical pharmacology
of antidepressant medication.We describe the major
developments that have occurred during the last
decades and list several directions for future develop-
ments.To prepare this text, we consulted clinical and
fundamental publications,and reviews and meta-analy-
ses covering many aspects of drug treatment of depres-
sive states,such as comparative efficacy,
1,2 the incidence
of side effects,
3 and dose–response curves.
4 Despite the
impressive list of discoveries,much research remains to
be done on the clinical, psychological, neuropsycholog-
ical, physiological, and neurochemical aspects in order
to obtain a coherent view of the mechanisms of depres-
sion and its treatment.
Antidepressant drugs of the past
The area of pharmacotherapy of depression started in
the 1950s, with landmark publications and discoveries
that still govern the manner in which we treat depres-
sion.In 1951,the tuberculostatic drug isoniazid was syn-
thesized, together with a series of variants, including
iproniazid, the first monoamine oxidase inhibitor
(MAOI).Iproniazid was first prescribed to patients suf-
fering from tuberculosis, a condition for which it was
efficacious, but induced more psychostimulation than
did isoniazid.Thorough clinical observations led to the
recognition of iproniazid’s antidepressant effects by
Kline and colleagues, Crane and colleagues, and Scher-
bel and colleagues.
5 Iproniazid was also suggested to be
potentially useful in coronary disease, lupus erythe-
matosus,and hypertension.In 1957,Kuhn described the
antidepressant effect of imipramine, a tricyclic com-
pound initially intended as an antipsychotic.
6 Tricyclic
antidepressants and MAOIs were rapidly demonstrated
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Tto be efficacious in severe depression and atypical
depression, as well as in other categories of depressive
disorders. However, iproniazid and other MAOIs
became obsolete because of the risk of hypotension and
hypertensive crisis;they are no longer marketed in many
countries and rarely prescribed in countries where they
remain available. Tricyclic antidepressants lead to
adverse reactions,such as hypotension,prolongation of
cardiac conduction, and drug-induced arrhythmia, side
effects related to antagonism of the cholinergic system
(dry mouth, blurred vision, constipation, urinary hesi-
tancy,amnesia,sedation,etc),and the histaminergic sys-
tem (sedation), as well as a quinidine-like effect on ion
channels. Despite these adverse drug reactions and the
fact that suicide attempts with MAOIs or tricyclic anti-
depressants generally need hospitalization, often in
intensive care units,the record was definitely in favor of
the use of these early antidepressants in major depres-
sion. It was generally considered that mild depression
did not respond to antidepressant therapy, an opinion
that has since changed considerably. Forty years ago,
clinical entities such as dysthymia,seasonal affective dis-
order, and premenstrual dysphoria were not yet identi-
fied as such,or were known under different names,often
referring to the broad category of neurosis rather than
mood disorders. Panic disorder, under the label of neu-
rosis, was treated with MAOIs by French clinicians, a
few years after the discovery of these compounds.In the
USA, Klein and Fink
7 used tricyclic antidepressants in
180 inpatients and selected 14 of them retrospectively,
on the basis of astute observations that led to the
description of panic attacks.Other early indications for
tricyclic antidepressants were enuresis in children and
premature ejaculation.On the basis of clinical and basic
observations, Bigger et al
8 proposed that imipramine
was a valuable antiarrhythmic medication;indeed,using
dosages of up to 300 mg/day,they demonstrated that the
number of ventricular extrasystoles could be consider-
ably reduced,and that repetitive ventricular tachycardia
could be suppressed.
9 In these relatively more recent
studies, nonpsychiatric patients received high doses of
tricyclic antidepressants, and it was confirmed that hal-
lucinations and delusions could be induced at these
doses.
Hypotheses concerning neurotransmitter changes during
depression, mostly for the monoamines,
10-12 but also for
other neurotransmitters,
13 led to several studies compar-
ing the efficacy of tricyclic antidepressants as a function of
monoamines and their metabolites in urine,blood,or cere-
brospinal fluid. Unfortunately, in most of these studies,
imipramine was considered to act mostly on noradrena-
line, and clomipramine on serotonin.This was not ideal,
since imipramine does have a small influence on sero-
tonin,and,more importantly,desmethylclomipramine,the
main metabolite of clomipramine, is a strong inhibitor of
noradrenaline reuptake.Therefore, these early studies
could not answer the question of subtypes of depression
with predominant dysfunctions in noradrenaline or sero-
tonin.
Another peculiar consequence of the prescription of tri-
cyclic antidepressants was the idea that several physical
complaints, such as headache, peptic ulcer symptoms,
arrhythmia,borderline hypotension,and prurigo,were in
fact the expression of masked depression.This was based
on the correct observation that these physical signs
responded to tricyclic antidepressant therapy, but the
conclusion was wrong: the pharmacological actions of
these drugs are sufficient to explain the clinical findings,
without the necessity of invoking a relationship between
physical complaints and unrecognized or masked depres-
sion. For example, cardiac arrhythmia responds to tri-
cyclic antidepressants, gastric hypersecretion is con-
trolled by the H2 antihistaminergic action of tricyclic
antidepressants,and moderate hypertension responds to
the α2 adrenolytic action of these agents.
Tertiary amines of the tricyclics (amitriptyline,
clomipramine, doxepin, imipramine, and trimipramine)
are demethylated into secondary amines (desipramine,
nortriptyline, and protriptyline), and these secondary
amines have been marketed for many decades.They tend
to be less sedating and induce fewer anticholinergic
effects.Other tricyclic antidepressants and tetracyclic com-
pounds include dothiepine, amoxapine, and maprotiline.
Although we listed tricyclic antidepressants under the
heading of drugs of the past, they are still prescribed
today. However, the precursors of catecholamines (L-
phenylanaline and L-tyrosine) or indolamines (5-hydroxy-
L-tryptophan and L-tryptophan) are no longer prescribed.
Antidepressant drugs of the present
There are currently between 10 and 20 different drugs
marketed as antidepressants,depending on the country.
The development of nontricyclic and non-MAOI anti-
depressants started with drugs such as fluvoxamine,
mianserin, moclobemide, and tianeptine; these drugs,
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tems in different ways, but generally with a narrower
configuration of pharmacological actions than the tri-
cyclic antidepressants.The modes of action of the recent
antidepressants are listed in Table I.
Tricyclic antidepressants and MAOIs were called first-
generation antidepressants,and selective serotonin reup-
take inhibitors (SSRI) and reversible and selective
inhibitors of monoamine oxidase A (RIMA) second-
generation antidepressants.Third-generation antide-
pressants include more recent molecules, such as mir-
tazapine, nefazodone, milnacipran, and reboxetine.The
distinction between first-, second-, and third-generation
antidepressants is not absolute:for example,mirtazapine
and nefazodone were recently launched onto the mar-
ket; however, they resemble mianserin and trazodone,
respectively, two compounds that were developed
decades ago. In terms of chronology, therefore, mirtaza-
pine and nefazodone should be considered as improved
second-generation antidepressants rather than members
of the third generation.The favorable therapeutic index
of second- and third-generation antidepressants is
reflected by lower rates of dropout, ie, 15% with SSRI
versus 20% or more with tricyclic antidepressants.
3 This
has enabled the study of the utility of the new antide-
pressants in many indications.Anxiety disorders became
a field of active research into the efficacy of antidepres-
sants.The goal was to find a medication that did not have
the disadvantage of inducing tolerance and dependence,
as was known to occur with benzodiazepines. (Thirty
years ago, the reverse situation was observed, in that
studies of benzodiazepines were set up in depression,
arguing that benzodiazepines had a far better therapeu-
tic index than the tricyclic antidepressants.) In a previous
review in this journal,
14 we proposed that the indications
for the newer antidepressants could be grouped under
the label of antidepressant-responsive disorders (ARD).
Table II gives a short list of these disorders.
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Table I. The mode of action of recent antidepressants.
*The antidepressant efficacy of these compounds (some of which are not on the market) remains to be confirmed clinically.
Selective serotonin reuptake inhibitors (SSRI) Citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline
Selective serotonin reuptake activators (SSRA) Tianeptine
Selective noradrenaline reuptake inhibitors (SNaRI) Reboxetine
Selective serotonin and noradrenaline reuptake inhibitors (SSNaRI) Milnacipran, venlafaxine (possibly paroxetine)
Noradrenaline α2 receptor antagonists Mianserin, mirtazapine
Serotonin 5-HT2 receptor antagonists Nefazodone, trazodone
Reversible and selective inhibitors of monoamine oxidase A  Moclobemide, toloxatone, selegiline*
(RIMA) and other monoamine oxidase inhibitors (MAOIs)
Dopamine and noradrenaline reuptake inhibitors Bupropion
5-HT1A serotonin receptor agonists Buspirone,* gepirone,* other azapyrones*
Benzodiazepine receptor agonists Alprazolam,* adinazolam*
Table II. Antidepressant-responsive disorders.
Mood disorders Major depression, with or without psychotic or melancholic
features, dysthymia, bipolar depression, premenstrual 
dysphoric disorder, seasonal affective disorder, depression 
in cases of physical disorders (dementia, Parkinson's 
disease, cerebrovascular accidents, lupus erythematosus,
multiple sclerosis, etc)
Anxiety disorders Panic disorders, phobia (agoraphobia, social phobia), 
obsessive-compulsive disorder, posttraumatic stress disorder
Other disorders Bulimia nervosa, anger attacks, chronic fatigue syndrome,
premature ejaculation, enuresis, trichotillomania, 
pathological gamblingThere exists a series of compounds with modes of action
other than those listed in Table I: S-adenosylmethionine
(a methyl donor), thyroid hormones, inositol, herbal
medicines (such as St John’s wort),mood stabilizers,cor-
tisol synthesis inhibitors, etc. Several of these com-
pounds are orphan drugs; most are still being studied.
Finally, biological therapies such as magnetic transcra-
nial stimulation,sleep deprivation,and vagal stimulation
are being studied in drug-resistant cases, as comple-
ments to treatment or as a replacement for electrocon-
vulsive therapy.
Antidepressant drugs of the future
Taken together,the three generations of antidepressants
mentioned above have the same level of clinical effica-
cy in the treatment of major depression,but compounds
from the second and third generations share the absence
of life-threatening side effects in overdose, as well as a
more favorable configuration of side effects at the usual
therapeutic doses,which constitutes a major advantage.
Antidepressants of the fourth generation are still to
come; they will also have a favorable configuration of
side effects,and,more importantly,will produce a high-
er rate of clinical response.These newer compounds
should fulfil several of the criteria for an ideal antide-
pressant molecule (Table III),at least more than the cur-
rently available antidepressants.
Whether an antidepressant that fulfils all the criteria in
Table III could be developed is a question for which
there is no answer;yet several goals seem reachable.The
first concerns better efficacy in terms of the percentage
of patients responding to the antidepressant.The tech-
niques of genomics and proteomics indicate the possi-
bility of identifying innumerable differences in gene or
protein expression between sick people and controls,
between patients with different clinical categories of dis-
orders, between patients responding or not responding
to treatment, and between those presenting or not pre-
senting given side effects of the medication.
15 Indeed,
several studies on the polymorphism of the serotonin
membrane transporter (5-HTT) suggest that this avenue
is worth pursuing.
16,17 These techniques might well lead
to the conclusion that finding an antidepressant that is
efficacious for almost every patient is wishful thinking,
while the modulation of treatment as a function of the
patient’s characteristics can improve the rate of favor-
able response. In the future, one might sell medication
in a package containing a recommendation (or a kit) to
identify laboratory values that are predictive of a good
response.
A second issue is that of the delay before the antide-
pressant effect.There are arguments in favor of the fea-
sibility of finding a drug therapy that induces remission
of depression within hours or days,rather than within 1
to 6 weeks. Indeed, spontaneous oscillations of normal
mood are very fast and other biological therapies, such
as sleep deprivation and electroconvulsive therapy, can
achieve rapid remission; moreover, addictive psycho-
stimulants (mostly cocaine) lead to immediate pleasure
and reward. Taken together, these facts suggest that
there are no inbuilt physiological limits leading to a time
span of several days as a mandatory constraint for a
change in mood. It might be, however, that the mecha-
nisms that induce a rapid change in mood are not the
same as those that maintain a normal mood.
The issue of an antidepressant that does not induce
mania in predisposed individuals is a rather difficult one,
since no efficacious antidepressant treatment is devoid
of this side effect,and since the shift from depression to
mania is a symptom of bipolar disorder as well as an
iatrogenic change.SSRIs and bupropion have been said
to induce less mania than tricyclic antidepressants, but
this statement needs confirmation.
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Table III. The characteristics of an ideal antidepressant.
• The percentage of responding patients should be high, at least 90%
• The response should be achieved within hours or days, not weeks or months
• The quality of therapeutic response should be good, without residual symptoms
• The risk of antidepressant-induced mania in bipolar disorder patients should be very low
• The physical discomfort of taking the medication should be very low
• There should be few drug–drug interactions
• The risk of death or severe side effects in case of overdose should be extremely low
• The medication should not be contraindicated in cases of major physical disorders (ie, few drug–disease interactions)
• The medication should regulate mechanisms leading to mood disorders, rather than have a symptomatic effectTable IV indicates a few directions for the development
of new antidepressants.These developments are based
on targets of psychotropic medication that are well
known (such as membrane receptors and transporters,
and monoamine enzymes), as well as on newer targets,
such as proteins for intercellular signaling (neurogenesis,
synaptogenesis, and neurodegeneration) and intracellu-
lar signal transduction (second and third messengers).
The pharmacological actions of antidepressants lead to
changes in secondary messengers, in the expression of
early genes, and in the synthesis of proteins, as well as
changes in synaptogenesis and neurogenesis, cerebral
metabolism, glial cell activity, secretion of stress hor-
mone,the equilibrium between neuroendocrine or neu-
roimmunology factors, and neuropeptide gene expres-
sion, etc.An effect common to several treatments, such
as antidepressants,electroconvulsive therapy,and sleep
deprivation, concerns the downregulation of corti-
cotropin-releasing hormone mRNA in the hypothala-
mus and the upregulation of glucocorticoid receptor
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Table IV. New and potential modes of action of antidepressants.
ACTH, adrenocorticotropic hormone; COMT, catechol-O-methyl-transferase; CRH, corticotropin-releasing hormone; GABA, γ-aminobu-
tyric acid; 5-HT, 5-hydroxytryptamine (serotonin); NK1, neurokinin 1; SSRI, selective serotonin-reuptake inhibitor.
Inhibitors of COMT COMT is an enzyme that participates in the catabolism of monoamines
SSRI molecules that antagonize 5-HT1A This would prevent the serotonin increase in the interstitial space, by decreasing
presynaptic (dendritic) receptors the serotonin-induced inhibition through 5-HT1A receptors of its own release
Modulation of endogenous compounds  Goto et al
18 have identified an endogenous compound that might act as an 
that inhibit 5-HT release SSRI. Modulation of this, or other compounds, could be an approach to 
an antidepressant
Modulation of melatonin Melatonin agonists might be developed as antidepressants
Inhibition of the  CRH antagonists might be antidepressants,
19 although there have been a few 
hypothalamic-pituitary-adrenal axis negative findings. Inhibitors of cortisol synthesis, such as ketoconazole
20 or
metyrapone,
21 have an antidepressant effect. Vasopressin also stimulates 
corticotropin (ACTH) secretion, but vasopressin antagonists have not been
clinically studied. Urocortine has a strong affinity for the two types of CRH 
receptors, as well as for the protein that binds CRH; it could therefore serve 
as a target for new antidepressants
Modulation of the cholinergic system Nicotinergic receptors have a modulatory action on the level of neuronal activity
and their agonists might have an antidepressant effect
Modulation of the GABAergic system Inverse agonists of central receptors for benzodiazepines are potential 
antidepressants, as well as GABAB receptor antagonists
Modulation of neuropeptide receptors  MK 869, an antagonists of the NK1 receptor, might not be as useful as initially
or enzymes thought, but other substance P antagonists are being developed.
22
Captopril was shown, on the basis of preliminary clinical findings, to have an 
antidepressant effect, perhaps because of inhibition of the peptidase that 
metabolizes endogenous opioids or other neuropeptides. Neurotrophins 
promote anatomical and functional aspects of neuronal circuits, and might 
become a new target for medication
Secondary messenger modulators Rolipram is an inhibitor of phosphodiesterase of type 4. It has not been 
marketed, but other medications along the same lines could be of interest, 
as well as compounds that influence protein kinases
Others Cytokine receptor antagonists might be antidepressants, based on an 
inflammatory hypothesis of depression. Paradoxical sleep suppressors such 
as modafinil will be studied by analogy with the efficacy of sleep deprivation. 
Adenosine receptor antagonists have antidepressant effects in animal models.
Glutamate and GABA neurotransmission might also become targets for 
new antidepressantsmRNA in the hippocampus, two effects that reflect a
negative feedback on the activity of the hypothalamic-
pituitary-adrenal axis.A challenging question will be to
establish which of the changes listed in Table IV repre-
sent primary actions of the antidepressant and which are
secondary changes, which might occur with drugs with
differing primary modes of action.
Clinical management of 
antidepressant drugs
The knowledge that has accumulated over the last 50
years now has several practical consequences.Dissemina-
tion of this information ensures that a higher percentage
of the afflicted population receives adequate therapy, ie,
that clinicians avoid both the indiscriminate prescription
of antidepressants and the abstention of prescription,
despite clear indications.The proposals listed below cover
some of the questions relative to the prescription of an
antidepressant; this checklist is not exhaustive and clini-
cians should consult the complete text of guidelines and
recommendations for further information, for example,
documents by Reesal and Lam
23 or Kennedy et al.
24
Evaluating the indications
All subtypes of depressive disorders are indications for
antidepressant therapy.Among the anxiety disorders,
panic disorder, obsessive-compulsive disorder, social
phobia, posttraumatic stress disorder, and generalized
anxiety are indications for antidepressants,mostly SSRIs.
Deciding to prescribe
The decision to prescribe an antidepressant should rely on
the evaluation of the severity of the symptoms,and the effi-
cacy of previous psychotherapy or other medications.The
decision as to whether the threshold of symptom severity is
met can vary according to the diagnosis and clinician’s and
the patient’s wishes. Severe cases of mood or anxiety dis-
orders should be treated with antidepressants, while the
decision to prescribe an antidepressant in moderate or even
mild cases can be taken over the course of a few weeks.
Evaluating the contraindications
A review of other drugs taken by the patient enables the
clinician to exclude the risk of drug–drug interactions.
Inhibition of hepatic cytochrome P450 enzymes is the
most cited pharmacokinetic interaction,but not all such
interactions are clinically relevant.The prescription of
other medications that influence serotonin (tramadol,
dextromethorphan, and sibutramine) can increase the
risk of serotonergic syndrome and represents a frequent
pharmacodynamic interaction. Drug–disease interac-
tions should also be excluded; these are numerous with
tricyclic antidepressants,but few with the newer antide-
pressants, which can be prescribed in patients suffering
from many cardiovascular, respiratory, or digestive dis-
eases. Renal or hepatic failure, physical frailty, and age
above 75 are reasons to use low doses (half a tablet or
less a day of any SSRI).
Choosing the first antidepressant and the dose
Tricyclic antidepressants and MAOI are outmoded and
should not be prescribed as first-line treatment because
their side-effect burden is too high.This opinion is not
shared by all experts, notably because the new drugs
are more expensive.The choice between SSRIs and the
other recent antidepressants depends on the conse-
quences of potential side effects for each patient and
the desirability of inducing sedation.With SSRIs, the
dosage should be one tablet a day to start with.There
are no indications that two tablets a day of SSRIs are
more useful than one, while they will induce more side
effects.Sedative compounds,such as mirtazapine,nefa-
zodone, or reboxetine, should be started at a low dose
of one tablet a day, with a rapid increase to the usual
doses within the first week of treatment.
Informing the patient
The clinician should explain which target symptoms can
be expected to improve, and should discuss with the
patient how to evaluate whether these goals are met.
Information on the risk of side effects early in the
course of treatment (anxiety, digestive symptoms, and
sleep fragmentation) and later (sexual inhibition)
should be provided.
Deciding to change the antidepressant
A minimum duration of 4 to 6 weeks with the same
antidepressant should be scheduled in case of depres-
sive states and anxiety disorders,unless the side effects
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decision to increase the dosage is often taken after 2 to
3 weeks of treatment, despite the lack of evidence-
based information on the utility of doing so.Changing
from one SSRI to another due to lack of efficacy can
give good results in cases of depression;the question of
whether this is also the case for anxiety disorders is not
clear.This change can be made from one day to the
next (under surveillance for serotonergic syndrome) or
after a period without antidepressant (under surveil-
lance for antidepressant withdrawal symptoms). In
case of side effects,changing to another antidepressant
with a similar pharmacological mode of action entails
a high risk of persistence of side effects,except for idio-
syncratic conditions such as allergy.Routine drug mon-
itoring of newer antidepressants in plasma is being
studied, and has very few indications for the present.
Obsessive-compulsive disorder stands apart, since
improvement can occur progressively over the course
of 2 to 4 months of antidepressant prescription.
Choosing the second antidepressant
Prescribing an antidepressant for treatment-resistant
patients often consists in shifting from one antidepres-
sant to another or in adding a second antidepressant
with a different mode of action;this can result in a good
therapeutic response. In cases of severely resistant
depressive states,the addition of lithium or thyroid hor-
mones or atypical antipsychotics constitute the next
steps.The prescriptions recommended for antidepres-
sant treatment resistance in case of anxiety disorders
are less well established.
Deciding on the duration of treatment
The duration of newly initiated antidepressant treat-
ment should be at least 6 months, preferably 1 year.
This rule prevails for all indications of antidepressants.
The risk of relapse is high in cases of dysthymia, panic
attacks, and obsessive-compulsive disorder. In case of
relapse, a prescription for 2 to 4 years can be sched-
uled. However, some patients might receive antide-
pressants for many years,when each attempt at lower-
ing and stopping medication is followed by a relapse.
Knowledge about the efficacy of long-term prescrip-
tions is limited, and not founded on evidence-based
medicine.
Addressing further questions
Here,we mention a few questions of clinical relevance.
What guides the choice of antidepressant?
There is no demonstration that any given class of anti-
depressants is more efficacious than another for the dif-
ferent categories of depression. Major depression with
atypical features was considered to respond better to
MAOIs than to other antidepressants.Also, there is no
biological test suggesting the choice of one antidepres-
sant over another for a given patient.It is generally rec-
ognized that patients who suffer from insomnia or who
have a high degree of anxiety might benefit more from
antidepressants that facilitate sleep and do not have the
risk of inducing anxiety during the first days of treat-
ment. This is sound clinical practice. However, even
patients who have sleep abnormalities and who are anx-
ious can respond favorably to an SSRI, despite the fact
that these medications can decrease sleep efficiency and
continuity, and carry the risk of exacerbating anxiety
during the first days or weeks of treatment.The authors
of this review consider that there is no indication left for
tricyclic antidepressants or MAOIs as first-line therapy
for any depressive or anxiety disorder.The reason for
this is,aside from the known side effects of tricyclic anti-
depressants,the long list of physical disorders that are a
contraindication to tricyclic antidepressants: heart fail-
ure, cardiac conduction disorder, hepatic insufficiency,
renal insufficiency, epilepsy, Parkinson's disease, cere-
brovascular disease,etc.
Are two antidepressants better than one?
The clinician can rightly ask whether there is an advan-
tage in combining two antidepressants to multiply the
targets of pharmacological actions and achieve a higher
rate of efficacy. In clinical practice, the combination of
two recent antidepressants is common. One such com-
bination has been known for years,ie,to add a sedative
to compensate for the stimulation due to an antidepres-
sant;trazodone,nefazodone,mianserin,and mirtazapine
can be used as sedatives,acting on sleep difficulties and
anxiety in patients receiving a stimulating antidepres-
sant.The combination of two antidepressants in other
situations should be limited. In treatment-resistant
patients,it is logical to combine antidepressants with dif-
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clinical configurations (for example,a stimulating SSRI
such as sertraline with a low or moderate dose of a
sedating compound such as mirtazapine or nefazodone).
There are no controlled clinical trials to confirm the
benefit of combining two antidepressants.
Is there a better response at higher  doses of
antidepressants?
Drug-monitoring studies have indicated a linear or
curvilinear relationship between efficacy and concen-
tration of tricyclic antidepressants such as imipramine,
desipramine, and nortriptyline. However, recent results
from the Danish University Antidepressant Group
(DUAG) have shown little difference between
clomipramine doses of 25,50,75,125,and 200 mg/day in
severely depressed patients.
25With fluoxetine,5 mg/day
seems to be clinically equivalent to 20 or 40 mg/day, in
terms of antidepressant effect.
26There are hints that ven-
lafaxine, nefazodone, and reboxetine are more effica-
cious at higher doses.The explanation put forward is
that the pharmacological mode of action differs as a
function of the dose, a point that is difficult to prove in
humans; for example, it has been said that at low doses
venlafaxine acts as an SSRI, and only at higher doses
does it influence the reuptake of noradrenaline.
27While
the existence of a better response at higher doses of
antidepressant is a subject of debate,there is consensus
about the increased risk of side effects at higher doses.
4
For example, dosages of 225 or 375 mg/day venlafaxine
lead to 24% and 30% dropouts,respectively,in compar-
ison to 17% for 75 mg/day and 5% for placebo.
28 Simi-
larly,dosages of 25 to 200 mg/day clomipramine lead to
3% to 27% dropouts,respectively.
25 In conclusion,high-
er doses of antidepressants might be tried in some treat-
ment-resistant patients, but the risk is that they might
not tolerate the side effects.
Does the effect of antidepressants wear off with time?
Loss of clinical efficacy for antidepressants has been
described in patients receiving tricyclic antidepressants,
29
MAOIs,
30 as well as recent antidepressants.
31,32This loss of
efficacy could occur in up to a third of all depressed
patients,for example,those having responded to fluoxe-
tine
33;it often manifests itself as apathy,fatigue,as well as
depression. It seems to represent a truly pharmacologi-
cal and physiological problem,possibly tied to secondary
changes in the dopaminergic system, although the fact
that it reflects the evolution of the psychiatric disorder
cannot be ruled out.Clinically,an increase in dosage can
lead to remission as well as to further aggravation of
symptoms.After a period with no medication, the same
medication can be reintroduced, often with success.
34
Improvement seen with placebo in clinical trials seems
to have a strong tendency to disappear over time.
35
What is the clinical relevance of antidepressants 
for subsyndromal mood or anxiety disorders?
Subsyndromal or subthreshold disorders are clinical
entities in which the presence of a psychiatric disorder
is suggested by minor symptoms, within a continuum
between normal state and an axis I diagnosis based on
Diagnostic and Statistical Manual of Mental Disorders,4th
edition (DSM-IV).
36 Although the efficacy of antide-
pressants has not been extensively evaluated in these
conditions,there are epidemiological data showing that
a subsyndromal state or the failure to achieve complete
remission predicts the occurrence of a first episode or
the recurrence of an axis I disorder.
37,38 ❏
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Los antidepresivos son muy eficaces en el trata-
miento de los trastornos afectivos, con una acción
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décadas la investigación sobre la fisiopatología de
los trastornos afectivos y ansiosos ha dado origen a
mucha información sobre los circuitos cerebrales, las
neurohormonas y los neurotransmisores que parti-
cipan en estos trastornos. Paralelamente los traba-
jos acerca de los aspectos biológicos y conductuales
de los antidepresivos, utilizando modelos animales
y nuevas técnicas bioquímicas, han conducido a una
mayor comprensión del mecanismo de acción de
estos fármacos. A pesar de esta impresionante lista
de descubrimientos se requiere de mucha investiga-
ción en los aspectos clínicos, psicológicos, neuropsi-
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Pharmacologie clinique des états dépressifs
Les antidépresseurs présentent une bonne efficaci-
té dans le traitement des troubles de l’humeur avec
des effets invariablement supérieurs à ceux d’un
placebo. Si les antidépresseurs plus récents ne peu-
vent se targuer d'une meilleure efficacité que les
molécules découvertes il y a 40 ou 50 ans, ils ont en
revanche des effets secondaires nettement
moindres, ce qui en améliore l’observance théra-
peutique. Ces avantages ont permis la prescription
de ces antidépresseurs pour des dépressions moins
sévères et pour divers troubles anxieux, avec un
bénéfice considérable pour les patients. Durant les
dernières décennies, la recherche sur la physiopa-
thologie des troubles anxieux et de l’humeur a
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réseaux neuronaux cérébraux, les neurohormones
et les neurotransmetteurs impliqués dans ces
pathologies. Parallèlement, nous avons une
meilleure compréhension du mode d’action des
antidépresseurs grâce aux travaux biologiques et
comportementaux sur ces médicaments, utilisant
des modèles animaux et de nouvelles techniques
biochimiques. Malgré cette impressionnante liste
de découvertes, il reste encore beaucoup à faire sur
le plan de la clinique, de la psychologie, de la neu-
ropsychologie, de la physiologie et de la neurochi-
mie, afin d’obtenir une description cohérente des
mécanismes physiopathologiques de la dépression
et de son traitement. Ceci devrait permettre de
mieux prévoir la qualité de la réponse aux diffé-
rents médicaments et ainsi d’individualiser le trai-
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